Table 1.
Participant characteristics
| BLSA | ADNI | |||
|---|---|---|---|---|
| A–, n = 71 | A+, n = 32 | A–, n = 61 | A+, n = 61 | |
| Age at baseline FTP PET (years) | 77 (70, 83) | 78 (73, 87) | 76 (70, 81) | 75 (71, 80) |
| Sex | ||||
| Female | 43 (61%) | 16 (50%) | 21 (34%) | 33 (54%) |
| Male | 28 (39%) | 16 (50%) | 40 (66%) | 28 (46%) |
| Race | ||||
| Asian or Pacific Islander | 4 (6%) | 1 (3%) | 1 (2%) | 0 |
| Black | 13 (18%) | 4 (12%) | 2 (3%) | 4 (7%) |
| White | 54 (76%) | 27 (84%) | 57 (93%) | 56 (92%) |
| Other | 0 | 0 | 1 (2%) | 1 (2%) |
| APOE status | ||||
| ε4– | 51 (72%) | 20 (62%) | 52 (85%) | 27 (44%) |
| ε4+ | 20 (28%) | 12 (38%) | 9 (15%) | 34 (56%) |
| Education (years) | 18 (16, 20) | 17 (16, 18) | 18 (16, 19) | 16 (14, 18) |
| 10-year cardiovascular disease risk | 0.16 (0.10, 0.23) | 0.13 (0.08, 0.18) | 0.28 (0.17, 0.37) | 0.17 (0.11, 0.28) |
| Diagnosis at baseline FTP PET | ||||
| Cognitively normal | 70 (99%) | 25 (78%) | 11 (18%) | 11 (18%) |
| Mild cognitive impairment | 1 (1%) | 7 (22%) | 50 (82%) | 50 (82%) |
| PET measures at baseline FTP PET | ||||
| Entorhinal cortex FTP SUVR (tau) | 1.02 (0.93, 1.1) | 1.07 (1.01, 1.23) | 1.65 (1.5, 2.02) | 2.06 (1.75, 2.58) |
| ITG FTP SUVR (tau) | 1.24 (1.19, 1.32) | 1.37 (1.29, 1.49) | 1.63 (1.57, 1.74) | 1.81 (1.63, 2.21) |
| ITG PiB R1 (cerebral blood flow) | 0.88 (0.86, 0.9) | 0.85 (0.82, 0.9) | — | — |
| ITG FDG SUVR (glucose metab.) | — | — | 1.22 (1.17, 1.31) | 1.21 (1.12, 1.32) |
| ITG volume (ITG-adj. residual, cm3) | −0.51 (−1.45, 0.45) | −1.38 (−2.54, 0) | −0.26 (−1.67, 1.1) | −1.61 (−3.12, 0.41) |
Continuous values are reported as median (interquartile range) and categorical values are reported as n (%). Age, diagnosis, PET measures, and MRI volumes are reported at the visit corresponding to or closest to the baseline FTP PET.
A– = amyloid negative; A+ = amyloid positive; ICV-adj. = intracranial volume-adjusted; — indicates that data are not available.